By Tony Fong

NEW YORK (GenomeWeb News) – In late 2006, Johnson & Johnson unit Veridex entered into a licensing deal with OncoMethylome Sciences for a prostate cancer test. The deal, the Belgian cancer research firm thought, would result in a steady stream of product revenues for years to come.

At the time, OncoMethylome had finished the initial research phase for the three-marker urine-based test, and Veridex planned to finish the research. If all went well, Veridex would commercialize the test.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.